Following the all-stock transaction, currently expected to close in Q2 2023, Adaptimmune shareholders will own ~75% and TCR² Therapeutics stockholders will own ~25% of the combined company Companies ...
Reprotech and TMRW Life Sciences today announced a strategic business combination, bringing together two leaders in fertility storage and technology to create the industry's most comprehensive, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results